$13+ Bn Digital Therapeutics (DTx) Markets, 2026: Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.
The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4%.
Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in digital therapeutics. However, a lack of awareness and access to digital therapeutics programs in developing countries, resistance from traditional healthcare providers, and unstable payment models are challenging the growth of this market.
The treatment/care-related applications segment accounted for the largest share of the digital therapeutics market in 2020.
Based on application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. The large share of this segment is attributed to the growing incidences of chronic diseases, the rising economic burden of their treatment, and investments in digital therapeutics to encourage the development of cost-effective and scalable treatment platforms for these conditions.
The diabetes segment is expected to dominate the market.
Based on the type of treatment/care-related application, the digital therapeutics market is further segmented into diabetes, CNS disorders, chronic respiratory diseases, musculoskeletal disorders, cardiovascular diseases, smoking cessation, medication adherence, gastrointestinal disorders, substance use disorders & addiction management, rehabilitation & patient care, and other treatment/care-related applications.
Diabetes commanded the largest share of 19.0% of the digital therapeutics market for treatment/care-related applications in 2020. The growing prevalence of diabetes, high healthcare costs associated with diabetes, and increasing government initiatives to reduce the burden with the help of cost-effective solutions are expected to drive the market growth in this segment.
B2B segment is expected to grow at the highest CAGR during the forecast period.
Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). This is attributed to growing awareness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products.
North America to be the largest and the fastest-growing regional market.
North America, which comprises the US and Canada, forms the largest market for digital therapeutics. Factors such as the influx of new startups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.
List of Companies Profiled in the Report
- Noom (US)
- Livongo Health (US)
- Omada Health (US)
- WellDoc (US)
- Pear Therapeutics (US)
- Proteus Digital Health (US)
- Propeller Health (US)
- Akili Interactive Labs (US)
- Better Therapeutics (US)
- Happify (US)
- Kaia Health (Germany)
- Mango Health (US)
- Click Therapeutics (US)
- Canary Health (US)
- Wellthy Therapeutics (India)
- Cognoa (US)
- Ayogo Health (Canada)
- Mindstrong Health (US)
- 2Morrow (US)
- Ginger (US)
- BehaVR Inc., (US)
- Mindable Health (Germany)
- Virta Health (US)
- Hinge Health (US)
- Doktor.se (Sweden)
For more information about this report visit https://www.researchandmarkets.com/r/78g7jt
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900